Join Manatt Health for the Next Two Webinars in Our Medicaid Managed Care Series.
It is difficult to exaggerate the impact of the opioid epidemic on the nation’s health.
On July 20, the Centers for Medicare & Medicaid Services (CMS) issued the new “Medicare Communications and Marketing Guidelines” (MCMG), which governs Medicare Advantage organizations (MAOs) and Part D plan sponsors.
The Trump administration (the Administration) has called for a reduction in drug spending.
In the late 1990s, healthcare providers began prescribing opioids at greater rates to treat chronic pain.
Over the past five years, the budgets of state Medicaid programs have been challenged by the introduction of new high-cost drugs into the marketplace.
There are six key drivers of the movement to a risk-based healthcare environment:
On September 8, 2017, Massachusetts submitted a waiver amendment request to the Centers for Medicare & Medicaid Services (CMS) to modify its MassHealth Section 1115 demonstration.
Gene therapy is the therapeutic delivery of polymers into a patient’s cells for the purpose of treating a disease. Polymers interfere with gene expression or correct mutations.
In its April 25, 2016 Medicaid managed care final rule, the Centers for Medicare and Medicaid Services (CMS) provides a revised framework for determining how managed care plans should be paid by state Medicaid programs.